Guenter Kraus

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

Hilde Azijn, Ilse Tirry, Johan Vingerhoets et al. · Antimicrobial Agents and Chemotherapy · 2009 · 291 citations · Full text

Hiv-1 Group M, Medicine, Human Retrovirus +15

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

Lieven Baert, Gerben van ‘t Klooster, Willy Dries et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2009 · 223 citations

Hiv Treatment, Nanomedicine, Long-acting Injectable Formulation +9

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors

Lotke Tambuyzer, Hilde Azijn, L Rimsky et al. · Antiviral Therapy · 2009 · 93 citations · Full text

Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel Concept Using Long-Acting Anti-Retroviral Drugs for Treating HIV-1

Marc Nischang, Roger P.M. Sutmuller, Gustavo Gers-Huber et al. · PLoS ONE · 2012 · 78 citations · Full text

TMC310911, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows <i>In Vitro</i> an Improved Resistance Profile and Higher Genetic Barrier to Resistance Compared with Current Protease Inhibitors

Inge Dierynck, Herwig Van Marck, Marcia Van Ginderen et al. · Antimicrobial Agents and Chemotherapy · 2011 · 35 citations · Full text